top of page
Atlas logo with compass star icon

5 Takeaways from PanAgora Pharma CX Summit | How AI Is Reshaping Life Sciences

1 day ago
4 min read

Yesterday, Atlas joined pharmaceutical and biotech leaders, innovators, and industry peers at PanAgora's 9th Annual Pharma CX AI & Tech Summit in Princeton, NJ. We're grateful for the opportunity to connect with so many thoughtful leaders. Discussions spanned the changing expectations of patients and HCPs, the need to modernize longstanding processes, and the growing importance of personalization, accessibility, and trust. Across these conversations, a broader theme emerged: AI's greatest impact may not be in what it enables us to do faster, but in how it challenges us to work differently.

Atlas's Rishi Dixit, Head of Strategic Solutions and Innovation, moderated a particularly thought-provoking panel, "Is Pharma Losing to AI?" Joined by industry leaders from CSL Behring, Tris Pharma, and formerly Harmony Biosciences, the discussion challenged assumptions: Is the bigger risk that AI companies will compete with pharma? Will pharma lose influence over the healthcare conversations patients and providers are already having? The discussion created reflection on how AI is changing not only the tools organizations use, but also their relationships with the people they serve.

Reflecting on the day's conversations, we see five interconnected areas of transformation that could shape how pharmaceutical and biotech organizations operate, engage, and deliver value in the years ahead.

 

1. Process Transformation | Rethinking the Work, Not Just Automating It


AI is exposing inefficiencies that organizations have worked around for years. Content generation, for example, can now happen at unprecedented speed, yet downstream processes like Medical, Legal, and Regulatory (MLR) review remain significant bottlenecks.

But the challenge goes beyond automation. Are we using AI to make existing processes faster, or are we rethinking whether those processes should operate differently in the first place?


The opportunity is to redesign end-to-end workflows, remove unnecessary friction, and build governance into processes that can operate at a fundamentally different pace.

 

2. Operating Model Transformation | From AI Tools to AI-Enabled Organizations


The conversation is shifting from experimenting with individual AI tools to orchestrating how people, AI agents, data, and systems work together.


Successful pilots demonstrate what technology can do. Scaling requires something more: clear accountability, coordinated workflows, connected data, quality controls, and a culture that encourages experimentation.


The challenge isn't proving AI works. It's creating the organizational conditions for AI to work reliably and at scale.

 

3. Experience Transformation | From Brand-Centric to Patient-Centric


One of the most memorable concepts from the conference was the idea of brands circling the patient, rather than the patient circling individual brands.


Pharma has traditionally organized engagement around brands, campaigns, and channels. But patients don't experience healthcare in channels. They navigate questions, decisions, barriers, and emotions throughout their care journey.


AI creates opportunities for more connected, personalized, and proactive experiences. But those experiences depend on understanding patient needs, improving accessibility, and ensuring the underlying data represents the diverse populations being served.


The shift is from managing individual interactions to designing experiences around the entire patient journey.

 

4. Outcome Transformation | Measuring Impact, Not Just Productivity


AI's value shouldn't be measured solely by how much faster we create content, analyze data, or complete tasks.


Consider the challenges surrounding prescription fulfillment, treatment initiation, and patient access. Better-connected data and AI-enabled interventions could help identify barriers earlier, coordinate support, and improve the likelihood that patients receive the care they need.


This requires shared accountability across functions and metrics that reflect actual outcomes, rather than isolated measures of activity or efficiency.


The question shifts from "How much more can we do?" to "What outcomes are we actually improving?"

 

5. Information Transformation | Pharma's Changing Role in the Healthcare Conversation


One of the provocative panel discussions "Is Pharma Losing to AI?" led by Atlas's Rishi Dixit opened up the dialogue on whether or not pharma is losing its influence over healthcare conversations.


Patients have always sought health information outside traditional healthcare settings. AI hasn't necessarily created that behavior; it's transformed it. Instead of searching through links, people can now ask questions, receive synthesized answers, and continue the conversation.


This changes the role of pharma's digital presence. Websites remain important, but increasingly as sources of credible, structured, and accessible information that AI systems can interpret and cite.


The opportunity isn't simply to appear in AI-generated answers. It's to help ensure the information patients and healthcare professionals receive is accurate, representative, and grounded in reliable evidence.

 

Our biggest takeaway at Atlas: These five transformations are deeply connected. Rethinking processes without evolving operating models, or delivering personalized experiences without trusted data, will only take organizations so far.


The real opportunity is to connect people, processes, data, and technology in ways that deliver measurable value.


The shape of work is changing while the purpose of the work, improving patient care, is becoming clearer than ever, and now is the time to rethink how to deliver on it.


Acknowledgments


Thank you to PanAgora Pharma and the entire speaking faculty for bringing together such valuable perspectives on the future of AI in life sciences. Insights shared by leaders representing Eisai, Boehringer Ingelheim, Novo Nordisk, CG Oncology, Insulet, CSL Behring, Tris Pharma, Gilead Sciences, Novartis, Merck, Takeda, and many other organizations helped inform these themes.


We appreciate the opportunity to contribute to the discussion and connect with the leaders and peers helping shape what's next for the industry.


 

Comments


bottom of page